Jia Liu (Liu Jia)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Ejection Fraction

Small Cell Lung Cancer

Top Venues

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Jia Liu, Shi Yuequan, Fang Jian, Lu Hongmin, Shui Yongjie, Liu Xiaoyan, Chen Minjiang, Xu Yan, Wang Mengzhao
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study. Immunotherapy (2024)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Haoran Zhang, Dongming Zhang, Jia Liu, Yuequan Shi, Xiaoyan Liu, Min-Jiang Chen, Wei Zhong, Jing Zhao, Yan Xu, Mengzhao Wang
Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC. Thoracic cancer (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer (2023)
Jia Liu, Min-Jiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Thoracic cancer 14 (8) (2023)